Independent fund research. Built on SEC filings.

How we research funds

ETF · Technology Sector · Global X

Global X Genomics & Biotechnology ETF (GNOM)

Ticker GNOM · Since 2019-04-05 · · Holdings as of May 31, 2026

Expense ratio
0.5%$50/yr per $10k
5-yr return
−13.3%annualized
1-yr return
+19.0%as of Dec 2025
Net assets
$55.8Mall share classes
Holdings
51

Bottom line

Is GNOM a good fund? The bottom line

GNOM is a managed technology sector ETF from Global X.

Annual fees run 0.5% — about $50 a year on every $10,000 invested, cheaper than 77% of technology sector funds we track.

It returned +19.0% over one year, −13.3% a year over five years (as of Dec 31, 2025, per its prospectus).

With $55.8 million in net assets and 51 holdings, its largest position is Guardant Health, Inc. (5.6%) and the top 10 make up 42.5% of the portfolio.

What stands out

  • Low cost: cheaper than 77% of technology sector peers

What to watch

  • 5-year return in the bottom quarter of its category

Updated Nov 19, 2026

What GNOM invests in

"The Global X Genomics & Biotechnology ETF (""Fund"") seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (""Underlying Index"")."

"The Fund invests at least 80% of its total assets in the securities of the Solactive Genomics Index (""Underlying Index""). The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Fund may lend securities representing up to one-third of the value of the Funds total assets (including the value of the collateral received). The Underlying Index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science, as well as applications thereof (collectively, ""Genomics Companies""), as defined by Solactive AG, the provider of the Underlying Index (""Index Provider""). Genomics Companies may include companies in the biotechnology industry. Companies in the biotechnology industry include companies that are involved in business…

From the fund's prospectus (filed Mar 27, 2026).

GNOM performance

Fund calendar-year total returns, 2020–2025 2020: +51.6%; 2021: −16.0%; 2022: −36.1%; 2023: −8.6%; 2024: −16.2%; 2025: +19.0% +51.6% 2020 −16.0% 2021 −36.1% 2022 −8.6% 2023 −16.2% 2024 +19.0% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
GNOM+19.0%−13.3%—
Technology Sector median+24.0%+10.0%+16.7%

Source: Fund prospectus, as of Dec 31, 2025

Full GNOM performance history →

What GNOM costs

On a $10,000 investment, GNOM's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.

See the full GNOM fee table →

GNOM top 10 holdings

#Holding% of fund
1Guardant Health, Inc.5.59%
2Illumina, Inc.4.82%
3Natera, Inc.4.15%
4Biomarin Pharmaceutical Inc.4.09%
5Arrowhead Pharmaceuticals, Inc.4.07%
6Legend Biotech Corp4.05%
7Praxis Precision Medicines Inc4.01%
8Twist Bioscience Corp3.97%
9Vertex Pharmaceuticals Incorporated3.95%
10CRISPR Therapeutics AG3.85%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 42.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to GNOM

More funds like GNOM →

GNOM FAQ

What is the expense ratio of GNOM?
GNOM's expense ratio is 0.5%, which works out to about $50 a year for every $10,000 invested. The prospectus estimates total costs of $628 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is GNOM a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 77% of technology sector peers; 5-year return in the bottom quarter of its category. This is general information, not personalized advice.
What does GNOM hold?
GNOM's largest holdings are Guardant Health, Inc. (5.6%), Illumina, Inc. (4.8%), Natera, Inc. (4.2%), Biomarin Pharmaceutical Inc. (4.1%), Arrowhead Pharmaceuticals, Inc. (4.1%). It holds 51 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is GNOM's 5-year return?
GNOM returned −13.3% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages GNOM?
GNOM is offered by Global X through Global X Funds.